GVS (GVS) Q2 2025 earnings summary

Executive summary

• Achieved record profitability and highest EBITDA margin since Q4 2021, with H1 2025 revenues of €215.6M, up 1.7% year-over-year at constant FX, and strong growth in core MedTech, Safety, and Healthcare & Life Sciences segments.

• Adjusted EBITDA rose 4.1% to €54.2M, margin at 25.1% for H1 and 26.2% in Q2 2025, reflecting disciplined execution and operational improvements.

• Adjusted net income increased 16.2% year-over-year to €26.2M, margin up to 12.1% from 10.5%, excluding FX effects.

• Strategic plan in development to address legacy low-margin businesses and optimize the portfolio.

Financial highlights

• Revenue grew to €215.6M, up 1.7% year-over-year excluding FX, with positive trends in core segments.

• Adjusted EBITDA margin improved by 90 bps to 25.1% for H1 2025; Q2 margin at 26.2%.

• Adjusted EBIT reached €39.5M, up 4.9% year-over-year, with an 18.3% margin.

• Net financial position at €268M as of June 2025, leverage ratio at 2.4x post-M&A.

• Price increases contributed 1.3% to revenue, with further 30-40 bps implemented to offset tariffs.

Outlook and guidance

• Full-year 2025 guidance calls for mid- to high single-digit revenue growth at constant FX, with acceleration in H2 from Whole Blood revenues.

• Adjusted EBITDA margin expected to rise by 150–250 bps versus 2024, including tariff impacts.

• Leverage ratio projected at ~2.2x by year-end, factoring in a €20M buyback.

• Anticipates strong cash generation in H2, with €40M ordinary cash expected.

• Dividend distribution remains a goal by year-end, subject to H2 performance.